Aeglea appoints Scott Burrows as CFO, Heidy Abreu King-Jones as CLO; prior CFO transitions to advisory role

Spyre Therapeutics, Inc.

Scott Burrows appointed CFO effective Sept 1, 2023, succeeding Jonathan Alspaugh; base salary $455K, target bonus 40%, sign-on $115K.
Heidy Abreu King-Jones appointed Chief Legal Officer & Corporate Secretary; both report to COO Cameron Turtle.
Jonathan Alspaugh transitions to strategic advisory role through Dec 31, 2023; he was President and CFO.
Burrows received inducement options for 10,121,441 shares and 3,373,814 RSUs; King-Jones options for 13,495,255 shares.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Burrows

Chief Financial Officer

SYRE · Spyre Therapeutics, Inc.

Effective: 2023-09-01
Filed: September 5, 2023, 7:59 PM ET

appointed Scott Burrows to succeed Jonathan Alspaugh as the Company’s Chief Financial Officer effective September 1, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Burrows was appointed as Chief Financial Officer at Spyre Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

appointed Scott Burrows to succeed Jonathan Alspaugh as the Company’s Chief Financial Officer effective September 1, 2023

View on SEC.gov

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-228076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.